XELJANZ® (TOFACITINIB CITRATE) RECEIVES MARKETING AUTHORIZATION IN THE EUROPEAN UNION.
The Pharma Data
AUGUST 22, 2021
today that the European Commission (EC) has approved XELJANZ ® (tofacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA) in patients two years of age and older who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).
52 
Let's personalize your content